Jiangsu Nhwa Pharmaceutical Co., Ltd.

China (People China (People's Republic)
Sector: Pharmaceuticals
Ticker: 002262
ISIN: CNE100000CG8
Factsheet Factsheet

Levered/Unlevered Beta of Jiangsu Nhwa Pharmaceutical Co., Ltd. ( 002262 | CHN)

Beta is a statistical measure that compares the volatility of a stock against the volatility of the broader market, which is typically measured by a reference market index. Since the market is the benchmark, the market's beta is always 1. When a stock has a beta greater than 1, it means the stock is expected to increase by more than the market in up markets and decrease more than the market in down markets. Conversely, a stock with a beta lower than 1 is expected to rise less than the market when the market is moving up , but fall less than the market when the market is moving down. Despite being rare, a stock may have a negative beta, which means the stock moves opposite the general market trend.
Jiangsu Nhwa Pharmaceutical Co., Ltd. shows a Beta of 1.41.
This is higher than 1. The volatility of Jiangsu Nhwa Pharmaceutical Co., Ltd. according to this measure is higher than the market volatility.

Beta (Ref: SSE Composite)
Levered betaUnlevered beta
1-Year1.411.53
2-Year1.271.38
3-Year1.261.37
More...
Valuation
EV/EBITDA LastEV/EBITDA(e) 2021EV/EBITDA NTM
Jiangsu Nhwa Pharmaceutical Co., LtFree trialFree trialFree trial
International PeersFree trialFree trialFree trial
Pharmaceuticals6.316.656.80
SSE Composite16.5010.109.38
China (People's Republic)20.9615.1113.44
More...
Stock Perf excl. Dividends (in CNY)
002262SSE CompositeRel. Perf.
Year-to-Date-8.6%2.9%-11.5%
1-Week-1.6%0.3%-1.9%
1-Month-3.0%0.5%-3.5%
1-Year-15.7%7.2%-22.9%
3-Year-16.0%26.3%-42.3%
5-Year21.8%18.7%3.1%
More...
International Peers - Jiangsu Nhwa Pharmaceutical Co., Ltd.
Company NameCtryMarket
Cap.
last (mUSD)
Jiangsu Nhwa Pharmaceut...CHN2 274
International Peers Median0.75
Yuhan Corp.KOR3 707
Chugai Pharmaceutical C...JPN61 465
Zhangzhou Pientzehuang ...CHN38 847
Otsuka Holdings Co., Lt...JPN21 939
Shanghai Pharmaceutical...CHN8 531
GPRV Analysis
Jiangsu Nhwa Pharmac...
Intl. Peers
U.S Patents No. 7,882,001 & 8,082,201
More...
Net Sales Chart
More...
Quotes Chart

1-Year Rebased Stock Chart

  • Jiangsu Nhwa Pharmaceutical Co., Ltd.
  • SSE Composite
More...

Did you know ?

Infront Analytics' Beta calculator allows you to define your input parameters for custom beta calculations.
The beta calculator offers additional flexibility, such as:
- Reference index: apply the same reference index for all companies in your list regardless of their country.
- Sampling frequency: choose between a weekly or a monthly sampling frequency for the closing prices.
- Debt for unlevered beta: choose the type of debt to be used for unlevered beta calculations.
- Additional beta statistics: calculate R-squared and T-value.

About Beta

Standard beta is co-called levered, which means that it reflects the capital structure of the company (including the financial risk linked to the debt level). Unlevered beta (or ungeared beta) compares the risk of an unlevered company (i.e. with no debt in the capital structure) to the risk of the market. Unlevered beta is useful when comparing companies with different capital structures as it focuses on the equity risk. Unlevered beta is generally lower than the levered beta. However, unlevered beta could be higher than levered beta when the net debt is negative (meaning that the company has more cash than debt).
Many different betas can be calculated for a given stock. The main common variables that affect beta calculations are the time period, the reference date, the sampling frequency for closing prices and the reference index.
The calculation divides the covariance of the stock return with the market return by the variance of the market return. Beta is used very often for company valuation using the Discounted Cash Flows (DCF) method. The discount rate is calculated using the Weighted Average Cost of Capital (WACC). The WACC is essentially a blend of the cost of equity and the after-tax cost of debt. The cost of equity is usually calculated using the capital asset pricing model (CAPM), which defines the cost of equity as follows: re = rf + β × (rm - rf)
Where:
rf = Risk-free rate
β = Beta (levered)
(rm - rf) = Market risk premium.